Business Context and Reporting Period
Cellyan Biotechnology Co., Ltd. furnished this Form 6-K for September 2026, filed September 23, 2026. The filing reports the results of the company’s extraordinary general meeting held September 21, 2026. The matters concerned the company’s share structure and governing documents, not operating results.
Meeting Participation and Results
| Item | For | Against | Abstain |
|---|---|---|---|
| Share consolidation | 360,889,111 | 6,847 | 0 |
| Fifth Amended Memorandum and Articles of Association | 360,889,111 | 6,846 | 1 |
Holders of 3,395,958 Class A shares and 7,150,000 Class B shares attended online or by proxy, representing 360,895,958 votes, or approximately 90.29% of the total voting power. Class B shares carry 50 votes per share, while Class A shares carry one vote per share.
Approved Share Consolidation and Governance Changes
- Shareholders approved a 1-for-20 consolidation of both Class A and Class B ordinary shares. Each 20 shares with a par value of US$0.001 will become one share with a par value of US$0.02.
- The consolidation is subject to an effective date confirmed by Nasdaq or a date to which Nasdaq raises no objection.
- No fractional shares will be issued; shareholders will receive one share of the applicable class in lieu of any resulting fractional share.
- Authorized share capital will remain US$1,000,000, but the authorized share count will change from 1,000,000,000 shares to 50,000,000 shares, consisting of 47,000,000 Class A shares and 3,000,000 Class B shares.
- Shareholders conditionally approved the Fifth Amended and Restated Memorandum and Articles of Association, effective upon the share consolidation.
Financial Metrics, Outlook, and Risks
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial performance metrics. It also does not provide management commentary on business outlook or operating risks.
The principal disclosed contingency is that the share consolidation requires Nasdaq confirmation or the absence of a Nasdaq objection. The amended governing documents are conditional on the consolidation becoming effective. The filing does not specify the effective date or any trading symbol, market-price, or depositary adjustment details.
Investor Verification Items
- Verify Nasdaq’s confirmation or non-objection and the official effective date of the 1-for-20 consolidation.
- Confirm the post-consolidation number of issued and outstanding Class A and Class B shares.
- Review how the consolidation affects the company’s Nasdaq listing, trading price, share-based awards, warrants, and other securities.
- Confirm that the Fifth Amended and Restated Memorandum and Articles of Association were filed and became effective with the Cayman Islands Registrar.
- Review subsequent filings for any operating results, financing activity, liquidity developments, or additional corporate actions.